TY - JOUR T1 - Safety and Efficacy of Platinum Agents plus Etoposide for Patients with Small Cell Lung Cancer with Interstitial Lung Disease JF - Anticancer Research JO - Anticancer Res SP - 1175 LP - 1179 VL - 33 IS - 3 AU - TATSUYA YOSHIDA AU - KIYOTAKA YOH AU - KOICHI GOTO AU - SEIJI NIHO AU - SHIGEKI UMEMURA AU - HIRONOBU OHMATSU AU - YUICHIRO OHE Y1 - 2013/03/01 UR - http://ar.iiarjournals.org/content/33/3/1175.abstract N2 - Background: The safety and efficacy of combination of platinum agents plus etoposide for patients with small cell lung cancer (SCLC) with pre-existing interstitial lung disease (ILD) is uncertain. Patients and Methods: Fifty-two patients received platinum agents plus etoposide as first-line chemotherapy for SCLC with pre-existing ILD. The clinical characteristics, treatment outcome and survival of these patients were retrospectively reviewed. Results: During first-line chemotherapy, only one (2%) out of the 52 patients developed an acute exacerbation of ILD. The median number of treatment cycles was four. The overall response rate was 69%. The median progression-free survival period was 4.5 months. The median survival time was 9.4 months. Thirty-three patients (63%) received at least one subsequent chemotherapy regimen, and five of these patients developed acute exacerbation of ILD. Conclusion: The combination of platinum agents plus etoposide is feasible and effective in SCLC patients with pre-existing ILD, compared with regimens after second-line chemotherapy. ER -